Target Name: CDCA7L
NCBI ID: G55536
Other Name(s): CDA7L_HUMAN | Cell division cycle-associated 7-like protein (isoform 1) | Cell division cycle associated 7 like, transcript variant 2 | CDCA7L variant 1 | DKFZp762L0311 | OTTHUMP00000158537 | OTTHUMP00000201868 | Transcription factor RAM2 | HR1 | CDCA7L variant 3 | cell division cycle associated 7 like | Cell division cycle-associated 7-like protein (isoform 2) | JPO2 | Cell division cycle-associated 7-like protein | Protein JPO2 | R1 | Cell division cycle-associated 7-like protein (isoform 3) | Cell division cycle associated 7 like, transcript variant 1 | RAM2 | transcription factor RAM2 | Cell division cycle associated 7 like, transcript variant 3 | CDCA7L variant 2 | OTTHUMP00000225272

CDCA7L: A Promising Drug Target and Biomarker for the Treatment of Cancer

Abstract:
CDCA7L, a protein expressed in various tissues and cell types, has been identified as a potential drug target and biomarker for the treatment of cancer. Its expression has been associated with cancer-related behaviors, such as tumor growth, metastasis, and poor prognosis. CDCA7L has also been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and invasion. The identification and characterization of CDCA7L as a potential drug target and biomarker make it an attractive target for cancer research and development.

Introduction:
Cancer is a leading cause of death worldwide, with over 20 million new cases and 5.5 million deaths in 2019. The development of new treatments for cancer remains a major challenge in the field of medicine. While advances in chemotherapy and radiation therapy have led to improvements in overall survival rates, there remains a need for more effective and targeted treatments.

CDCA7L: A Potential Drug Target

CDCA7L, which stands for Cervical adenocarcinoma-associated gene 7, is a gene that has been identified as potentially targeting cancer cells. It is expressed in various tissues and cell types, including breast, ovarian, and prostate tissues, and has been associated with cancer-related behaviors, such as tumor growth, metastasis, and poor prognosis.

CDCA7L has been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and invasion. It has been shown to promote the formation of cancer-associated extracellular matrix (ECM) components, such as E-cadherin, and to inhibit the degradation of E-cadherin. These functions contribute to the maintenance of cancer cell survival and the formation of tumors.

CDCA7L has also been shown to play a role in the regulation of angiogenesis, the process by which new blood vessels form in response to tissue damage or injury. It has been shown to promote the proliferation and migration of cancer cells, which is essential for their growth and the formation of tumors.

CDCA7L as a Biomarker

The identification of CDCA7L as a potential drug target and biomarker for cancer has implications for the development of new treatments. By targeting CDCA7L, researchers could potentially inhibit its functions and reduce the growth and spread of cancer cells.

One approach to targeting CDCA7L is to use small molecules, such as drugs that bind to its extracellular domain or its transmembrane domain. These drugs could potentially inhibit the functions of CDCA7L, including its role in cell adhesion, migration, and invasion.

Another approach to targeting CDCA7L is to use antibodies that recognize and target its specific epitopes. These antibodies could potentially bind to CDCA7L and prevent it from interacting with its target proteins, such as E-cadherin.

Conclusion:
CDCA7L is a protein that has been identified as potentially targeting cancer cells. Its expression is associated with cancer-related behaviors and its functions in the regulation of cellular processes, including cell adhesion, migration, and invasion, make it an attractive target for cancer research and development. The identification and characterization of CDCA7L as a potential drug target and biomarker make it an important step in the development of new treatments for cancer. Further research is needed to understand its full potential as a drug target and biomarker.

Protein Name: Cell Division Cycle Associated 7 Like

Functions: Plays a role in transcriptional regulation as a repressor that inhibits monoamine oxidase A (MAOA) activity and gene expression by binding to the promoter. Plays an important oncogenic role in mediating the full transforming effect of MYC in medulloblastoma cells. Involved in apoptotic signaling pathways; May act downstream of P38-kinase and BCL-2, but upstream of CASP3/caspase-3 as well as CCND1/cyclin D1 and E2F1

More Common Targets

CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1 | CDS2